Robaxin — Competitive Intelligence Brief

Robaxin (METHOCARBAMOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscle Relaxant [EPC]. Area: Pain.

marketed Muscle Relaxant [EPC] Carbonic anhydrase 1 Pain Small molecule

Target snapshot

Robaxin (METHOCARBAMOL) — Hikma.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Robaxin TARGET	METHOCARBAMOL	Hikma	marketed	Muscle Relaxant [EPC]	Carbonic anhydrase 1	1957-01-01
Sodium Nitrite	SODIUM NITRITE	Hope Pharms	marketed	sodium nitrite	Carbonic anhydrase 1	2011-01-01
Syprine	TRIENTINE	Bausch Health	marketed	Copper Chelator	Carbonic anhydrase 14	1985-01-01
Plasma-Lyte A In Plastic Container	Sodium Acetate	Pfizer	marketed	sodium acetate	Carbonic anhydrase 1, Carbonic anhydrase	1983-01-01
Ethamide	ETHOXZOLAMIDE	Pfizer	marketed	ethoxzolamide	Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13	1982-01-01
Sulfamylon	MAFENIDE	Rising	marketed	Methylated Sulfonamide Antibacterial	Carbonic anhydrase 12	1969-01-01
Avc	SULFANILAMIDE	Pharmobedient	marketed	sulfanilamide	Carbonic anhydrase 13	1965-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2044-10-09 — Robaxin · 12390439 · Formulation · US

Sponsor landscape (Muscle Relaxant [EPC] class)

1. Hikma · 1 drug in this class
2. Johnson & Johnson · 1 drug in this class
3. Mylan Speciality Lp · 1 drug in this class
4. Pfizer · 1 drug in this class